CNS-directed therapy is a delicate balance between toxicity and efficacy. Each child requires just enough therapy to prevent relapse (too cold) while avoiding toxicity (too hot). This will be achieved by accurate biomarkers, trials of less toxic agents, and ensuring that drugs efficiently reach their targets in the CNS.